Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study.
about
A brief history of the development of antidepressant drugs: from monoamines to glutamateThe effectiveness of prefrontal theta cordance and early reduction of depressive symptoms in the prediction of antidepressant treatment outcome in patients with resistant depression: analysis of naturalistic data.Early PTSD symptom trajectories: persistence, recovery, and response to treatment: results from the Jerusalem Trauma Outreach and Prevention Study (J-TOPS)A genome-wide association study of a sustained pattern of antidepressant responseGenetic moderation of child maltreatment effects on depression and internalizing symptoms by serotonin transporter linked polymorphic region (5-HTTLPR), brain-derived neurotrophic factor (BDNF), norepinephrine transporter (NET), and corticotropin reAssessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care.Early Improvement in Psychosocial Function Predicts Longer-Term Symptomatic Remission in Depressed Patients.Treating major depression with yoga: A prospective, randomized, controlled pilot trialAntidepressant Response Trajectories and Associated Clinical Prognostic Factors Among Older Adults.Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episodeSymptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical TrialDepression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptomsTrajectories of change in anxiety severity and impairment during and after treatment with evidence-based treatment for multiple anxiety disorders in primary careSudden gains in prolonged exposure and sertraline for chronic PTSD.Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement.Early switching strategies in antidepressant non-responders: current evidence and future research directions.Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder.Treating to target in major depressive disorder: response to remission to functional recovery.Depression and Schizophrenia: Cause, Consequence, or Trans-diagnostic Issue?Tryptophan: the key to boosting brain serotonin synthesis in depressive illness.Typologies of psychiatric admissions and length of inpatient stay in Italy.Systems genetics analysis of pharmacogenomics variation during antidepressant treatment.Piperine Augments the Protective Effect of Curcumin Against Lipopolysaccharide-Induced Neurobehavioral and Neurochemical Deficits in Mice.The BDNF Val(66)Met polymorphism is associated with escitalopram response in depressed patients.Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder.
P2860
Q27028050-2C7A57C7-796A-4F81-97EF-006869A7E0CCQ30825123-20A9FCD5-6128-4B15-9481-6F32C8CD58EBQ31130665-A9840D1A-F4EE-415F-AA0F-55B3B3ABB4DBQ34347951-251F504F-B4DC-418B-88F4-40F2DD3379A2Q34574243-D7E9F70F-B530-4D38-9239-A261E8FC0F9CQ36185585-BC9BF191-DF7F-456F-9BD1-9A469C3065BFQ36234571-5F0F5420-141D-473F-95FB-9F1CF1084A75Q36310727-C1FF446A-FCD2-4734-B688-CFF4EE86CD15Q36477780-AD51EA5C-21EB-4603-8477-437536355F31Q36591265-36BB000F-92C1-4E2B-97BC-6F7CB566EF8BQ36737606-451CFA4F-850C-48D4-AD9B-3A4F4D0BADF1Q37208565-79492916-17AA-4D63-B8C3-87E943250DA0Q37517692-6D66CC29-D7EE-4266-9FC9-0052A98126E1Q37595431-BFFFDBA8-B880-4913-8359-1AE9DD46C2A5Q38066275-BAA9EB30-C89B-4B0A-8F42-8DB2AD718538Q38211978-E5CA831E-7274-4F11-9581-9E9ABA3EA65CQ38476909-F535CBF2-772E-41A4-A69A-75967E1B068BQ38619996-630266D4-6556-4067-8BE1-CF2271421856Q38673546-CEA2B77F-D850-4B38-B8B9-A2D286689FAEQ38898192-33D03DF1-95CC-4CDC-98CB-C1D70EBECF2CQ39374641-94ACDF1E-A6EE-49EB-85A8-3932F5214718Q39859615-C6C72A7B-CB90-4CAD-A44A-63B3B9355578Q47912001-406DAD8C-2327-4FB8-97D8-6632263B72DBQ48061279-0E8BD663-306B-4F8E-9EFE-09B1F6DE3A81Q48244608-F5BFB086-3A04-4580-9779-935A1E70A03EQ51761102-3EE8E9CD-3139-45B4-9CB5-FC231BA1AA11
P2860
Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Early and delayed onset of res ...... for Depression (GENDEP) study.
@ast
Early and delayed onset of res ...... for Depression (GENDEP) study.
@en
Early and delayed onset of res ...... erapeutic Drugs for Depression
@nl
type
label
Early and delayed onset of res ...... for Depression (GENDEP) study.
@ast
Early and delayed onset of res ...... for Depression (GENDEP) study.
@en
Early and delayed onset of res ...... erapeutic Drugs for Depression
@nl
prefLabel
Early and delayed onset of res ...... for Depression (GENDEP) study.
@ast
Early and delayed onset of res ...... for Depression (GENDEP) study.
@en
Early and delayed onset of res ...... erapeutic Drugs for Depression
@nl
P2093
P50
P356
P1476
Early and delayed onset of res ...... for Depression (GENDEP) study.
@en
P2093
Aleksandra Rajewska-Rager
Ana Petrovic
Anne Farmer
Astrid Zobel
Julien Mendlewicz
Peter McGuffin
P304
P356
10.4088/JCP.10M06419
P50
P577
2011-11-01T00:00:00Z